Granules India Limited · NSE:GRANULES
Granules India — Q4 FY22 Earnings Presentation
16 slides from Granules India's earnings presentation, May 18, 2022
Slide 1: Presentation to the Analysts/Investors
Gg GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Dated: May 18, 2022 To, National Stock Exchange
Slide 2: Q4 and FY22 Earnings Presentation
Granules India Limited Q3 Earnings Presentation Granules India Limited Q4 and FY22 Earnings Presentation 1
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q4 FY22 Financial Highlights
Q4 FY22 Financial Highlights (In ₹ Mn) Income from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 5,039 10,300 9,968 2,020 2,014 4,648 1,927 4,607 4,578 1,737 4,517 8,883 1,512 8,499 25.3% 7,993 23.7% 57.3% 54.2% 17.0% 17.4% 18.5% 50.9% 17.4% 46.6% 48.9%
Slide 5: FY22 Financial Highlights
FY22 Financial Highlights (In ₹ Mn) Income from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 20000 57.0% 60.0% 12000 30.0% 26.4% 16.3% 37,649 19500 55.0% 50.0% 10000 25.0% 19000 50.0% 32,375 19.2% 18500 18813 45.0% 8000 8552 20.0% 18000 18463 40.0% 6000
Slide 6: Geographical Mix
Q4FY22 Revenue spilt by Market, Molecules and Segments (In ₹ Mn) Growth in Europe and Latin America All segments grew vs last year Q4FY21 Q4FY22 6.1% 5.9% 10,300 Geographical Mix 8.1% 7,993 Segment Revenue 13.5% 11.9% 5,254 57.0% 8.9% 52.4% 4,611 2,568 21.5% 1,444 14.5% 1,938 2,478 North America Eur
Slide 7: Financial and Business Summary for Q4FY22 and FY22
Financial and Business Summary for Q4FY22 and FY22 The Board of Directors have recommended final dividend of 75 paise per equity share of Re.1/- each in addition to interim dividend of 75 paise per equity share of Re.1/- each paid during the year. Revenue for Q4FY22 stood at INR 10,300 Mn, growt
Slide 8: Q4 FY22 Financial Ratios
Q4 FY22 Financial Ratios (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow* Free Cash Flow 1,453 506 1,328 324 1.03 1.00 0.93 0.78 1,005 49 0.67 7,322 6,966 754 6,576 6,298 5,752 -303 233 -718 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22
Slide 9: ANDA/Dossier filing status
ANDA/Dossier filing status GPI IP GIL IP Filing Status Total USA USA Europe Canada South Africa UK Approved 23 25 2 2 52 Tentatively Approved 1 1 2 To be approved 5 9 4 3 2 2 25 Total Products 29 35 6 5 2 2 79 Total GPI products include: ANDA/Dossier filed - Therapeutic area wise CII – 7 Analgesics
Slide 10: Revenue trend – percentage share from Core and Other Molecules
Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 17% 15% 16% 14% 15% 16% 14% 14% 15% 19% 17% 18% 19% 17% 16% 3% 16% 1%34% 26% 3% 3% 5% 5% 3% 6% 3% 3% 4% 3% 17% 18% 13% 19% 25% 6% 19% 29% 25% 17% 33% 26% 86% 83% 85% 84% 21% 21% 86% 86% 83% 85%
Slide 11: 5-year trajectory: Key Ratios and Cash Flow
5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 10,000 3.5 160 1.2 4,000 120.0% 9,082 2,919 9,000 8,704 135 138 3,000 140 125 3.0 100.0% 1 8,000 3.1 117 1,615 114 2,000 6,966 2.5 120 109 7,000 6,138 6,058 0.8 1,00
Slide 12: 5-year trajectory: Revenue and Profitability
5-year trajectory : Revenue and Profitability (In ₹Mn) Revenue Gross Profit & Gross Margin 37,649 20,000 18,463 18,813 170.0% 18,000 32,375 150.0% 16,000 130.0% 25,986 14,000 13,177 110.0% 22,792 12,000 10,236 57.0% 90.0% 16,918 10,000 7,955 14,353 7,556 70.0% 8,000 50.7% 50.0% 6,000 52.6% 52.6% 47.
Slide 13: 5-year trajectory: Market and Segment mix
5-year trajectory: Market and Segment mix (In ₹Mn) Higher revenue contribution coming from Finished Dosage contribution in value going FD segment share increased to 40% to 52% regulated market, 73% of total revenues up in last 5yrs 5% 5% 4% 6% 5% 15% 14% 12% 20% 20% 8% 10% 9% 19,442 9% 12% 39.9% 47.
Slide 14: Granules 2.0
Granules 2.0 Strengthening the Drive cost leadership and EBITDA transformation, through strong focus on cost Core management Commercial excellence incl. new product launch management capabilities to propel growth in US and other geographies. B2B business with focus on value-add APIs. Build the formu
Slide 15: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 16: Corporate address
Mr. Krishna Raghunathan VP Finance and Investor Relations Email: krishna.raghunathan@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Ashish Chovatia +91 9930044680 ashish.chovatia@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Flo